All In Biotech

Drug Trial Radar · NCT02794571

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors

Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

518

Actual

Start

May 23, 2016

Primary completion

Nov 13, 2024

Study completion Nov 13, 2024

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

Conditions

  • Advanced/Metastatic Tumors

Interventions

  • AtezolizumabDrug

    Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

  • TiragolumabDrug

    Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.

  • CarboplatinDrug

    Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.

  • CisplatinDrug

    Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.

  • PemetrexedDrug

    Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.

  • PaclitaxelDrug

    Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.

  • EtoposideDrug

    Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.

  • CapecitabineDrug

    Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.

  • BevacizumabDrug

    Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: From Baseline to the end of Cycle 1 (up to 21 days)
  2. Percentage of Participants with Adverse Events (AEs) Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0Time frame: From Baseline up to 90 days after last dose of study treatment or until initiation of another systemic anti-cancer therapy (up to approximately 8 years)
  3. Number of Cycles with TiragolumabTime frame: From Baseline to last dose (up to approximately 8 years)
  4. Phase Ia and Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to TiragolumabTime frame: Day 1 up to 8 years
  5. Phase Ib: Percentage of Participants with ADAs to AtezolizumabTime frame: Day 1 up to 8 years

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • University of California Los Angeles

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • Kinghorn Cancer Centre; St Vincents Hospital

    Darlinghurst, New South Wales, Australia

  • Peter MacCallum Cancer Center

    North Melbourne, Victoria, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Institut Bergonie CLCC Bordeaux

    Bordeaux, France

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, France

  • Institut Curie

    Paris, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • National Cancer Center Hospital

    Tokyo, Japan

  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research

    Tokyo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitario HM Sanchinarro-CIOCC; Oncología Médica

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • ICO L'Hospitalet; Servicio de oncologia medica

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Sant Andreu de la Barca, Barcelona, Spain

  • Clinica Universitaria de Navarra; Servicio de oncología

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.